Capital01
Financing Strategy
Current Funding Round:Series A – SEK 40M
Use of Proceeds
- 20% Clinical Development
- 20% Product Development
- 15% Business Development
- 15% Working Capital
- 15% IP & Regulatory
- 15% Commercial Readiness
Investor RelationsFinancial
Financial Information
Here you will find financial information, corporate documents, ownership information and investor information relating to Auxesis Pharma. The company is developing a patented technology platform for local treatments in pharmaceuticals and dermatology, supported by a growing and diversified product portfolio.
Market opportunity
Global Market Opportunity
OTC Skin & Pain Relief
- 01The global topical pain & skin care market is estimated to reach approximately USD 12.2 billion by 2027.
- 02The market is projected to grow at approximately 5.2% CAGR.
- 03Europe and North America together represent approximately 68% of global demand.
- 04Auxesis also addresses broader markets across dermatology, pharmaceuticals, cosmeceuticals and veterinary medicine.
Regional distribution
* Market data and forecasts are based on external market data and the assumptions used in Auxesis Pharma's current investor materials.
Strategy02
Strategic Objectives
- Create value through clinical and regulatory milestones
- Develop and expand the patented technology platform
- Build a diversified portfolio across pharmaceuticals and dermatology
- Establish strategic licensing and distribution partnerships
- Create potential future exit pathways through licensing, M&A or the capital markets
A solid ownership structure
Roar Adelsten
Owns 64.4 percent privately and through companies according to the latest stated ownership information.
Other Shareholders
Other shareholders collectively own 35.6 percent and consist primarily of private individuals and smaller companies.
Shareholders
Auxesis has approximately 800 shareholders. Euroclear Sweden maintains the company's share register. The ownership information above is as of December 31, 2025.
Investment Case01
Positioned for the Next Stage of Development
One technology platform with multiple product opportunities across pharmaceuticals and dermatology
Clinical and regulatory development of ASA.P® is at an advanced stage
The IP portfolio is expanding through international patent applications and new patent programs
Diversified product portfolio across human pharmaceuticals, veterinary medicine and dermatology
Capital-efficient development model supported by external specialist partners
Multiple strategic pathways through licensing, partnerships and M&A
Ownership
Ownership Structure
Founders & Management65%
Early Shareholders7%
Strategic / Industrial0%
Employee Incentive Program (ESOP)0%
Free Float / Other28%
Management team
A cross-functional team with experience in pharmaceutical development, international Life Science, business development, product strategy and commercialization.
01
Roar Adelsten
Chair of the Board & Founder
Founder and entrepreneur with nearly 30 years of experience in pharmaceuticals and MedTech.
Expertise and Background
- Founder & Entrepreneur
- Nearly 30 years in Pharma & MedTech
- International Business Development
Contribution:
Drives long-term business development, innovation and strategic positioning.
02
Peter Åberg
CEO & Board Observer
Life Science executive with experience in pharmaceutical development, sustainability and international leadership.
Expertise and Background
- Life Science Executive
- Pharmaceutical Development
- Sustainability & Business Development
Contribution:
Leads the company's operational and strategic development.
Governance
Experienced Board and Management
Auxesis Pharma combines entrepreneurship, scientific expertise, pharmaceutical development and international business experience.
Board
Auxesis Pharma Board of Directors
01
Roar Adelsten
Chair of the Board & Founder
02
Anna Tenstam
Executive Board Director
03
Lars-Olof Peterson
Board Director
04
Peter Åberg
CEO & Board Observer
05
Peter Hedberg
Board Observer
Management
Auxesis Pharma Management Team
01
Roar Adelsten
Chair of the Board & Founder
02
Peter Åberg
CEO & Board Observer
Financial calendar
Key dates for financial reports, annual general meetings and other investor events.
Upcoming events
Clinical Development Update
An update on ASA.P® and the company's ongoing clinical development program.
Investor Update
A summary of the company's development, financing and strategic priorities for the next phase.
2026 Year-End Update
Key milestones from the year and an overview of Auxesis Pharma's priorities for 2027.
Financial reports
01
Annual Report 2025
August 2025
02
Annual Report 2024
June 2025
03
Annual Report 2023
June 2024
Investor Relations
Contact IR
Do you have questions about the company, financing or ownership structure, or would you like to arrange a meeting with Auxesis Pharma?
+46 (0)8-771 43 00